(HealthDay News) — Treatment with continuous positive airway pressure (CPAP) doesn’t appear to reduce risk of adverse cardiovascular-related outcomes or mortality, according to a meta-analysis published in the July 11 issue of the Journal of the American Medical Association.

Jie Yu, MD, of the Peking University Third Hospital in Beijing, and colleagues analyzed data from 10 clinical trials, including 7266 people with sleep apnea.

The investigators found no connection between CPAP use and a reduced risk of adverse cardiovascular events, cardiovascular mortality, all-cause mortality, acute coronary syndrome, stroke, or heart failure.

“The use of PAP, compared with no treatment or sham, was not associated with reduced risks of cardiovascular outcomes or death for patients with sleep apnea,” the authors conclude. “Although there are other benefits of treatment with PAP for sleep apnea, these findings do not support treatment with PAP with a goal of prevention of these outcomes.”

Reference

  1. Yu J, Zhou Z, McEvoy RD, et al. Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea.  JAMA. 11 July 2017. doi: 10.1001/jama.2017.7967